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All the reported compounds exhibited weak, moderate, or high antimicrobial activity and cytotox-
icity. Especially, compound 4i showed the best antimicrobial activity and cytotoxicity of all the 1,4-
dihydropyridine derivatives, with an MIC value of 11.5 lM, 12.2 lM and a CTC50 value of 27 lM.
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Infectious diseases caused by microorganisms are one of the
main reasons of illness in the world. The search for new
antibacterial drugs is a never ending story because of the
increasing resistance of the microbial pathogens.1 Despite
many available antibiotics and chemotherapeutic agents
78 K. Elumalai et al.available, the emergence of old and new antibiotic resistant
bacterial strains in the last decades leads to a substantial need
for new classes of antibacterial agents.2 The increasing inci-
dence of infection caused by the rapid development of bacterial
resistance to most of the known antibiotics is a serious health
problem now a days. While many factors may be responsible
for mutations of the microbial genomes, it has been widely
demonstrated that the incorrect use of antibiotics can greatly
increase the development of resistant genotypes. As the
multidrug-resistant bacterial strains proliferate; the necessity
for effective therapy has stimulated research into the design
and synthesis of novel antimicrobial molecules.3
The credit of the first synthesis of dihydropyridine is attrib-
uted to Arthur Hantzsch for work performed a century ago.4
The Hantzsch 1,4-dihydropyridines (DHPs) synthesis involves
the reaction of 1,3-dicarbonyl compounds with aldehyde and
ammonia. During the past decades, the scope of the original
cyclocondensation reaction was gradually extended by varia-
tion of all three building blocks, allowing access to a large
number of structurally diverse multifunctionalized DHPs.
The discovery of a dihydropyridine (dihydronicotinamide
derivative, NADH), ‘‘hydrogen transferring coenzyme” at
1930s consequently became important in the biological system.
Therefore, various studies have been generated on the bio-
chemical properties of dihydropyridine and their bioisosteres
dihydropyrimidines.5 When substituent’s on the left side differ
from the right side of a 1,4-DHPs, the molecule is chiral, with
C(4) as the stereogenic center. The enantiomers of an unsym-
metrical 1,4-DHPs usually differ in their biological activities
and could even have an exact opposite activity profile.6
The 1,4-dihydropyridine derivatives are of interest because
of their potential biological activity and use in therapeutics
such as antimicrobial,7,8 antihypertensive,9 anticonvulsant,10
anti-inflammatory,11 antioxidant,12,13 anticancer,14–17 antico-
agulant,18 antitubercular, and19–21 anti viral agents,22 and cal-
cium channel modulators of the nifedipine type.23–26 The
chemical structure of isoniazid provides a most valuable
molecular template for the development of agents able to inter-
act with a wide variety of biological activities.27–29 Hence, it
was thought worthwhile to synthesize new molecules by incor-
porating isoniazid with 1,4-dihydropyridines moieties in a sin-
gle molecular framework and to evaluate their antimicrobial
activity and cytotoxicity.
2. Experimental
2.1. Materials and methods
All chemicals were supplied by E. Merck (Germany) and S.D
fine chemicals (India). Melting points were determined by the
open tube capillary method and are uncorrected. The purity
of the compounds was checked on thin layer chromatography
(TLC) plates (silica gel GF) in the solvent system, ethanol,
chloroform, ethyl acetate (4:3:3); the spots were located under
iodine vapors or UV light. The IR spectrums were obtained on
a Perkin-Elmer 1720 FT-IR spectrometer (KBr Pellets). The
1H NMR spectra were recorded or a Bruker DRX-300
(300 MHz FT-NMR) spectrometer using DMSO-d6 as solvent
and TMS as internal standard. The 13C NMR spectra was
recorded on AV-III 400 MHz spectrometer using DMSO-d6
as solvent and TMS as internal standard. The chemical shiftsare expressed in d ppm and the following abbreviations are
used; s= singlet, bs= broad singlet, d= doublet, t= triplet,
m=multiplet. Mass spectra were obtained using Shimadzu
LCMS 2010A under ESI ionization technique. Elemental anal-
yses (C, H, and N) were performed on Perkin Elmer model
240C analyzer.
2.2. Preparation of N-(3-oxobutanoyl) isonicotinohydrazide (3)
A mixture of isoniazid 1, ethyl acetoacetate (0.01 M) and a cat-
alytic amount of potassium t-butoxide in 95% ethanol was
refluxed for 3 h. The formed reddish brown liquid was then
heated on a water bath to remove the alcohol formed during
the reaction. After allowing the reaction mixture to cool, crude
crystals were obtained. Purification was performed by stirring
crude crystals with cold diethyl ether for approximately 10 min
by using a mechanical stirrer. Allowing it to stand for 15 min,
followed by filtration, resulted in the third compound in a pure
form of N-(3-oxobutanoyl) isonicotinohydrazide 3.
2.3. General procedure for the preparation of 1,4-dihydropy-
ridines by one pot-multicomponent, Hantzsch method of
synthesis
The mixture of N-(3-oxobutanoyl) isonicotinohydrazide 3
(0.01 M), appropriate aldehyde (0.005 M), a catalytic amount
of barium nitrate and 3 ml of 25–30% aqueous ammonia solu-
tion were transferred to a round bottom flask containing 15 ml
of ethanol. The reaction mixture was refluxed for 11–18 h. One
milliliter (ml) of 25% aqueous ammonia solution was added
for every 3 h during the reflux. The reactions were monitored
through TLC using a suitable solvent system. Soon after the
reaction was completed, the reaction mixture was allowed to
cool. The solid product formed was filtered and washed with
cold methanol to get Hantzsch 1,4-dihydropyridines.
2.4. Analytical data
2.4.1. N-(3-oxobutanoyl) isonicotinohydrazide 3
Reddish-brown solid, M.P: 171–173 C; yield: 63%; IR (KBr,
cm1): 3364 (NAH), 2981 (Ali-CAH), 1731 (C‚O, ketone),
1674 (C‚O, amide), 1567 (C‚C), 1344 (CAN); 1H NMR
(DMSO-d6) d: 2.03 (s, 3H, CH3), 3.38 (s, 2H, CH2), 7.92 (d,
2H, Ar-H), 8.02 (s, 1H, NH), 8.14 (s, 1H, NH), 9.01 (d, 2H,
Ar-H); MS (m/z): (M + 1) calculated 221.07; found 221.12;
calculated for C10H11N3O3: C, 54.24; H, 5.01; N, 19.00; found
C, 54.29; H, 5.07; N, 19.02.2.4.2. N3,N5-diisonicotinyl-2,6-dimethyl-4-phenyl-1,4-
dihydropyridine-3,5-dicarbohydrazide (4a)
Dark-brownish solid; M.P: 257–259 C; yield-56%; IR (KBr,
cm1): 3294 (NAH), 3081 (Ar-CAH), 3010 (Ali-CAH), 1667
(C‚O, amide), 1486 (Ar-C‚C), 1328 (CAN); 1H NMR
(DMSO-d6) d: 1.78 (s, 6H, (CH3)2), 4.58 (s, 1H, CH), 6.21
(bs, 1H, NH), 7.04–7.15 (m, 5H, Ar-H), 7.94 (d, 2H, (Ar-H)),
8.01 (d, 2H, (Ar-H)), 8.08 (s, 1H, NH), 8.13 (s, 1H, NH),
8.17 (s, 1H, NH), 8.22 (s, 1H, NH), 9.03 (d, 2H, (Ar-H)),
9.10 (d, 2H, (Ar-H)); 13C NMR (125 MHz, DMSO-d6, d ppm):
16.9 (CH3), 17.0 (CH3), 45.1 (CH), 102.2 (2ArC), 123.4
(4ArC), 125.8 (1ArC), 128.2 (2ArC), 129.1 (2ArC), 140.9
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(2C‚O), 165.2 (2C‚O); MS (m/z): (M + 1) calculated
511.19; found 511.13; calculated for C27H25N7O4: C, 63.40;
H, 4.93; N, 19.17; found C, 63.46; H, 4.99; N, 19.23.2.4.3. N3,N5-diisonicotinyl-2,6-dimethyl-4-styryl-1,4-
dihydropyridine-3,5-dicarbohydrazide (4b)
Light gray-colored solid; M.P: 238–240 C; yield-71%; IR
(KBr, cm1): 3286 (NAH), 3092 (Ar-CAH), 2994 (Ali-
CAH), 1664 (C‚O, amide), 1468 (Ar-C‚C), 1367 (CAN);
1H NMR (DMSO-d6) d: 1.74 (s, 6H, (CH3)2), 3.94 (s, 1H,
Ali-CH), 6.05 (s, 1H, Ali-CAH), 6.16 (bs, 1H, NH), 6.38 (s,
1H, Ali-CAH), 7.12 (s, 1H, Ar-H), 7.25 (d, 2H, Ar-H), 7.38
(s, 1H, Ar-H), 7.96 (d, 2H (Ar-H)), 8.12 (s, 1H, NH), 8.19 (s,
1H, NH), 8.27 (s, 1H, NH), 8.34 (s, 1H, NH), 9.13 (d, 2H,
(Ar-H)); 13C NMR (125 MHz, DMSO-d6, d ppm): 16.9
(CH3), 17.2 (CH3), 31.2 (CH), 102.7 (2ArC), 121.7 (‚C),
122.8 (4ArC), 126.4 (2ArC), 128.1 (ArC), 128.6 (2ArC),
130.5 (‚C), 135.2 (ArC), 139.8 (2ArC), 149.5 (2ArC), 149.9
(4ArC), 164.9 (2C‚O), 165.2 (2C‚O); MS (m/z):
(M + 1) calculated 537.21; found 537.24; calculated for
C29H27N7O4: C, 64.79; H, 5.06; N, 18.24; found C, 64.85; H,
5.11; N, 18.29.2.4.4. N3,N5-diisonicotinyl-2,6-dimethyl-4-(2-nitrophenyl)-1,4-
dihydropyridine-3,5- dicarbohydrazide (4c)
Light-greenish solid; M.P: 259–261 C; yield: 66%; IR (KBr,
cm1): 3304 (NAH), 3108 (Ar-CAH), 2982 (Ali-CAH), 1669
(C‚O, amide), 1453 (Ar-C‚C), 1372 (CAN); 1H NMR
(DMSO-d6) d: 1.75 (s, 6H, (CH3)2), 4.49 (s, 1H, CH), 6.19
(bs, 1H, NH), 7.32 (d, 2H, Ar-H), 7.56 (s, 1H, Ar-H), 7.92
(d, 2H, (Ar-H)), 7.99 (d, 2H, (Ar-H)), 8.04 (s, 1H, Ar-H),
8.08 (d, 2H, (Ar-H)), 8.22 (s, 1H, NH), 8.25 (s, 1H, NH),
8.27 (s, 1H, NH), 8.29 (s, 1H, NH), (d, 2H, Ar-H), 9.11 (d,
4H, (d, 2H, Ar-H)); 13C NMR (125 MHz, DMSO-d6, d ppm):
16.7 (CH3), 17.8 (CH3), 36.3 (CH), 102.8 (2ArC), 121.0 (ArC),
122.7 (4ArC), 126.7 (ArC), 130.0 (ArC), 131.8 (ArC), 134.8
(ArC), 140.9 (2ArC), 149.0 (ArC), 149.8 (4ArC), 164.8
(2C‚O), 165.2 (2C‚O); MS (m/z): (M + 1) calculated
556.18; found 556.14; calculated for C27H24N8O6: C, 58.27;
H, 4.35; N, 20.13; found C, 58.32; H, 4.31; N, 20.16.
2.4.5. 4-(2-Chlorophenyl)-N3,N5-diisonicotinyl-2,6-dimethyl-
1,4-dihydropyridine-3,5-dicarbohydrazide (4d)
Light-bluish solid; M.P: 283–285 C; yield: 74%; IR (KBr,
cm1): 3318 (NAH), 3112 (Ar-CAH), 2956 (Ali-CAH), 1672
(C‚O, amide), 1481 (Ar-C‚C), 1384 (CAN); 1H NMR
(DMSO-d6) d: 1.72 (s, 6H, (CH3)2), 4.52 (s, 1H, CH), 6.22
(bs, 1H, NH), 7.02–7.17 (m, 4H, Ar-H), 7.92 (d, 2H, (Ar-H),
7.98 (d, 2H, (Ar-H)), 8.06 (s, 1H, NH), 8.12 (s, 1H, NH),
8.19 (s, 1H, NH), 8.24 (s, 1H, NH), 9.12 (d, 2H, (Ar-H)),
9.15 (d, 2H, (Ar-H)); 13C NMR (125 MHz, DMSO-d6, d ppm):
16.8 (CH3), 16.9 (CH3), 35.9 (CH), 102.8 (2ArC), 118.1 (ArC),
122.7 (4ArC), 124.3 (ArC), 129.6 (ArC), 135.2 (ArC), 140.9
(2ArC), 143.1 (ArC), 148.2 (2ArC), 149.5 (2ArC), 149.8
(4ArC), 164.8 (2C‚O), 165.2 (2C‚O); MS (m/z): (M + 1)
calculated 545.15; found 545.21; calculated for C27H24ClN7O4:
C, 59.40; H, 4.43; N, 17.96; found C, 59.46; H, 4.48; N,
17.93.2.4.6. N3,N5-diisonicotinyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-
dihydropyridine-3,5-dicarbohydrazide (4e)
Light-yellowish solid; M.P: 262–264 C; yield: 76%; IR (KBr,
cm1): 3305 (NAH), 3126 (Ar-CAH), 2934 (Ali-CAH), 1669
(C‚O, amide), 1471 (Ar-C‚C), 1376 (CAN); 1H NMR
(DMSO-d6) d: 1.76 (s, 6H, (CH3)2), 4.49 (s, 1H, CH), 6.17
(bs, 1H, NH), 7.47 (d, 2H, Ar-H), 7.94 (d, 2H, Ar-H), 7.97
(d, 2H, Ar-H), 8.04 (d, 2H, (Ar-H), 8.12 (s, 1H, NH), 8.18
(s, 1H, NH), 8.22 (s, 1H, NH), 8.29 (s, 1H, NH), 9.04 (d,
2H, (Ar-H)), 9.13 (d, 2H, (Ar-H)); 13C NMR (125 MHz,
DMSO-d6, d ppm): 16.7 (CH3), 16.8 (CH3), 43.9 (CH), 102.8
(2ArC), 122.7 (4ArC), 126.7 (ArC), 127.8 (ArC), 128.7
(ArC), 130.4 (ArC), 134.4 (ArC), 140.8 (2ArC), 143.6 (ArC),
149.5 (2ArC), 149.8 (4ArC), 164.8 (2C‚O), 165.2 (2C‚O);
MS (m/z): (M + 1) calculated 556.18; found 556.13; calculated
for C27H24N8O6: C, 58.27; H, 4.35; N, 20.13; found C, 58.32;
H, 4.39; N, 20.19.
2.4.7. 4-(3-Chlorophenyl)-N3,N5-diisonicotinyl-2,6-dimethyl-
1,4-dihydropyridine-3,5-dicarbohydrazide (4f)
Light gray-colored solid; M.P: 284–286 C; yield 73%; IR
(KBr, cm1): 3312 (NAH), 3118 (Ar-CAH), 2952 (Ali-
CAH), 1673 (C‚O, amide), 1478 (Ar-C‚C), 1362 (CAN);
1H NMR (DMSO-d6) d: 1.74 (s, 6H, (CH3)2), 4.47 (s, 1H,
CH), 6.23 (bs, 1H, NH), 6.96–7.12 (m, 4H, Ar-H), 7.96 (d,
2H, Ar-H), 8.01 (d, 2H, Ar-H), 8.05 (s, 1H, NH), 8.08 (s,
1H, NH), 8.13 (s, 1H, NH), 8.19 (s, 1H, NH), 9.02 (d, 2H,
Ar-H), 9.09 (d, 2H, Ar-H); 13C NMR (125 MHz, DMSO-d6,
d ppm): 16.7 (CH3), 16.8 (CH3), 44.5 (CH), 102.7 (2ArC),
122.8 (4ArC), 125.9 (ArC), 127.1 (ArC), 128.9 (ArC), 130.0
(ArC), 134.2 (ArC), 140.9 (2ArC), 143.5 (ArC), 149.5
(2ArC), 149.8 (4ArC), 164.8 (2C‚O), 165.2 (2C‚O); MS
(m/z): (M + 1) calculated 545.15; found 545.19; calculated
for C27H24ClN7O4: C, 59.40; H, 4.43; N, 17.96; found C,
59.44; H, 4.48; N, 18.02.
2.4.8. 4-(3-Fluorophenyl)-N3,N5-diisonicotinyl-2,6-dimethyl-
1,4-dihydropyridine-3,5-dicarbohydrazide (4g)
Light-greenish solid; M.P: 297–299 C; yield 77%;IR (KBr,
cm1): 3318 (NAH), 3124 (Ar-CAH), 2936 (Ali-CAH), 1668
(C‚O, amide), 1473 (Ar-C‚C), 1380 (CAN); 1H NMR
(DMSO-d6) d: 1.73 (s, 6H, (CH3)2), 4.45 (s, 1H, CH), 6.20
(bs, 1H, NH), 6.76–7.06 (m, 4H, Ar-H), 7.94 (d, 2H, Ar-H),
8.02 (d, 2H, Ar-H), 8.12 (s, 1H, NH), 8.17 (s, 1H, NH), 8.24
(s, 1H, NH), 8.27 (s, 1H, NH), 9.03 (d, 2H, Ar-H), 9.11 (d,
2H, Ar-H); 13C NMR (125 MHz, DMSO-d6, d ppm): 16.7
(CH3), 16.8 (CH3), 45.0 (CH), 102.7 (2ArC), 112.4 (ArC),
116.1 (ArC), 122.8 (4ArC), 124.6 (ArC), 130.3 (ArC), 140.8
(2ArC), 143.8 (ArC), 149.5 (2ArC), 149.8 (4ArC), 162.7
(ArC), 164.8 (2C‚O), 165.2 (2C‚O); MS (m/z): (M + 1) cal-
culated 529.18; found 529.24; calculated for C27H24FN7O4: C,
61.24; H, 4.57; N, 18.52; found C, 61.28; H, 4.63; N, 18.49.
2.4.9. 4(4-Chlorophenyl)-N3, N5-diisonicotinyl-2,6-dimethyl-
1,4-dihydropyridine-3,5-dicarbohydrazide (4h)
Light-bluish solid; M.P: 281–283 C; yield 81%; IR (KBr,
cm1): 3304 (NAH), 3118 (Ar-CAH), 2922 (Ali-CAH), 1671
(C‚O, amide), 1478 (Ar-C‚C), 1374 (CAN); 1H NMR
(DMSO-d6) d: 1.75 (s, 6H, (CH3)2), 4.47 (s, 1H, CH), 6.23
(bs, 1H, NH), 6.98–7.16 (m, 4H, Ar-H), 7.95 (d, 2H, Ar-H),
80 K. Elumalai et al.8.04 (d, 2H, Ar-H), 8.09 (s, 1H, NH), 8.13 (s, 1H, NH), 8.17 (s,
1H, NH), 8.21 (s, 1H, NH), 9.06 (d, 2H, Ar-H), 9.13 (d, 2H,
Ar-H); 13C NMR (125 MHz, DMSO-d6, d ppm): 16.7 (CH3),
16.8 (CH3), 44.9 (CH), 102.7 (2ArC), 122.8 (4ArC), 128.7
(2ArC), 130.5 (2ArC), 131.3 (ArC), 140.2 (ArC), 140.9
(2ArC), 149.4 (2ArC), 149.8 (4ArC), 164.8 (2C‚O), 165.2
(2C‚O); MS (m/z): (M+ 1) calculated 545.15; found
545.20; calculated for C27H24ClN7O4: C, 59.40; H, 4.43; N,
17.96; found C, 59.45; H, 4.49; N, 18.01.
2.4.10. 4(4-Fluorophenyl)-N3,N5-diisonicotinyl-2,6-dimethyl-
1,4-dihydropyridine-3,5-dicarbohydrazide (4i)
Dark-brownish solid; M.P: 306–308 C; yield: 65%; IR (KBr,
cm1): 3313 (NAH), 3140 (Ar-CAH), 2938 (Ali-CAH), 1668
(C‚O, amide), 1484 (Ar-C‚C), 1381 (CAN); 1H NMR
(DMSO-d6) d: 1.78 (s, 6H, (CH3)2), 4.44 (s, 1H, CH), 6.18
(bs, 1H, NH), 6.86–7.06 (m, 4H, Ar-H), 7.93 (d, 2H, Ar-H),
8.01 (d, 2H, Ar-H), 8.08 (s, 1H, NH), 8.12 (s, 1H, NH), 8.16
(s, 1H, NH), 8.19 (s, 1H, NH), 9.02 (d, 2H, Ar-H), 9.10 (d,
2H, Ar-H); 13C NMR (125 MHz, DMSO-d6, d ppm): 16.7
(CH3), 16.8 (CH3), 45.0 (CH), 102.8 (2ArC), 115.3 (2ArC),
122.7 (4ArC), 130.6 (2ArC), 137.8 (ArC), 140.8 (2ArC),
149.4 (2ArC), 149.7 (4ArC), 159.8 (ArC), 164.8 (2C‚O),
165.2 (2C‚O); MS (m/z): (M + 1) calculated 529.18; found
529.13; calculated for C27H24FN7O4: C, 61.24; H, 4.57; N,
18.52; found C, 61.29; H, 4.63; N, 18.47.
2.4.11. N3,N5-diisonicotinyl-2,6-dimethyl-4-(pyridine-2-yl)-1,4-
dihydropyridine-3,5-dicarbohydrazide (4j)
Light-bluish solid; M.P: 293–295 C; yield: 73%; IR (KBr,
cm1): 3313 (NAH), 3144 (Ar-CAH), 2952 (Ali-CAH), 1670
(C‚O, amide), 1476 (Ar-C‚C), 1368 (CAN); 1H NMR
(DMSO-d6) d: 1.74 (s, 6H, (CH3)2), 4.48 (s, 1H, CH), 6.22
(bs, 1H, NH), 7.27 (d, 2H, Ar-H), 7.78 (s, 1H, Ar-H), 7.95
(d, 2H, Ar-H), 8.02 (d, 2H, Ar-H), 8.09 (s, 1H, NH), 8.13 (s,
1H, NH), 8.15 (s, 1H, NH), 8.17 (s, 1H, NH), 8.69 (s, 1H,
Ar-H), 9.02 (d, 2H, Ar-H), 9.10 (d, 2H, Ar-H); 13C NMRN
O
H
N
NH2
+
O
OC2H5
O N
a
Figure 1 Synthesis of compounds (4a–4m). Reagents and conditio
butoxide; (b) C2H5OH, barium nitrate 25–30% aqueous ammonia sol(125 MHz, DMSO-d6, d ppm): 16.7 (CH3), 16.8 (CH3), 31.7
(CH), 102.7 (2ArC), 120.9 (ArC), 122.7 (4ArC), 124.1 (ArC),
136.1 (ArC), 140.8 (2ArC), 148.7 (ArC), 149.5 (2ArC), 149.8
(4ArC), 158.5 (ArC), 164.8 (2C‚O), 165.2 (2C‚O); MS
(m/z): (M + 1) calculated 512.19; found 512.25; calculated
for C26H24N8O4: C, 60.93; H, 4.72; N, 21.86; found C, 60.90;
H, 4.76; N, 21.90.
2.4.12. N3,N5-diisonicotinyl-2,6-dimethyl-4-(pyridine-3-yl)-1,4-
dihydropyridine-3,5-dicarbohydrazide (4k)
Light-yellowish solid; M.P: 273–275 C; yield: 80%; IR (KBr,
cm1): 3308 (NAH), 3158 (Ar-CAH), 2940 (Ali-CAH), 1668
(C‚O, amide), 1456 (Ar-C‚C), 1372 (CAN); 1H NMR
(DMSO-d6) d: 1.76 (s, 6H, (CH3)2), 4.44 (s, 1H, CH), 6.17
(bs, 1H, NH), 7.31 (s, 1H, Ar-H), 7.72 (s, 1H, Ar-H), 7.93
(d, 2H, Ar-H), 8.01 (d, 2H, Ar-H), 8.11 (s, 1H, NH), 8.15 (s,
1H, NH), 8.19 (s, 1H, NH), 8.23 (s, 1H, NH), 8.59 (d, 2H,
Ar-H), 9.07 (d, 2H, Ar-H), 9.15 (d, 2H, Ar-H); 13C NMR
(125 MHz, DMSO-d6, d ppm): 16.7 (CH3), 16.8 (CH3), 44.9
(CH), 102.8 (2ArC), 122.7 (4ArC), 123.0 (ArC), 132.5 (ArC),
134.3 (ArC), 140.8 (2ArC), 147.4 (ArC), 149.4 (2ArC), 149.8
(4ArC) 150.1 (ArC), 164.9 (2C‚O), 165.2 (2C‚O); MS
(m/z): (M + 1) calculated 512.19; found 512.22; calculated
for C26H24N8O4: C, 60.93; H, 4.72; N, 21.86; found C, 60.99;
H, 4.77; N, 21.92.
2.4.13. N3,N5-diisonicotinyl-2,6-dimethyl-4-(pyridin-4-yl)-1,4-
dihydropyridine-3,5-dicarbohydrazide (4l)
Light gray-colored solid; M.P: 233–235 C; yield: 62%; IR
(KBr, cm1): 3298 (NAH), 3184 (Ar-CAH), 2966 (Ali-
CAH), 1673 (C‚O, amide), 1487 (Ar-C‚C), 1378 (CAN);
1H NMR (DMSO-d6) d: 1.78 (s, 6H, (CH3)2), 4.47 (s, 1H,
CH), 6.24 (bs, 1H, NH), 7.32 (d, 2H, Ar-H), 7.95 (d, 2H, Ar-
H), 8.03 (d, 2H, Ar-H), 8.04 (s, 1H, NH), 8.09 (s, 1H, NH),
8.12 (s, 1H, NH), 8.17 (s, 1H, NH), 8.63 (d, 2H, Ar-H), 9.04
(d, 2H, Ar-H), 9.11 (d, 2H, Ar-H); 13C NMR (125 MHz,
DMSO-d6, d ppm): 16.7 (CH3), 16.7 (CH3), 45.0 (CH), 102.7N
O
HN
NH
O
O
O
HN NH
O
O
+
b RCHO
N
H
R
N
H
O
H
N
O
N
N
H
O
H
N
O
N
ns: (a) reflux 3.0 h, 10 ml of ethanol (95%) and potassium tert-
ution, and reflux for 11–18 h.
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(2ArC), 149.8 (4ArC), 149.9 (2ArC), 151.2 (ArC), 164.9
(2C‚O), 165.1 (2C‚O); MS (m/z): (M + 1) calculated
512.19; found 512.15; calculated for C26H24N8O4: C, 60.93;
H, 4.72; N, 21.86; found C, 60.97; H, 4.74; N, 21.84.
2.4.14. 4-(Furan-2-yl)-N3,N5-diisonicotinyl-2,6-dimethyl-1,4-
dihydropyridine-3,5-dicarbohydrazide (4m)
Light gray-colored solid; M.P: 245–247 C; yield: 64%; IR
(KBr, cm1): 3307 (NAH), 3162 (Ar-CAH), 2978
(Ali-CAH), 1671 (C‚O, amide), 1475 (Ar-C‚C), 1368
(CAN); 1H NMR (DMSO-d6) d: 1.74 (s, 6H, (CH3)2), 4.44
(s, 1H, CH), 5.86 (s, 1H, Ar-H), 6.20 (bs, 1H, NH), 6.20
(s, 1H, (Ar-H), 7.23 (s, 1H, (Ar-H), 7.96 (d, 2H, Ar-H), 8.01Figure 2 General mechanism of H(d, 2H, Ar-H), 8.09 (s, 1H, NH), 8.13 (s, 1H, NH), 8.17 (s,
1H, NH), 8.22 (s, 1H, NH), 9.03 (d, 2H, Ar-H), 9.10 (d, 2H,
Ar-H); 13C NMR (125 MHz, DMSO-d6, d ppm): 16.1 (CH3),
16.2 (CH3), 32.9 (CH), 102.7 (2ArC), 106.7 (ArC), 110.5
(ArC), 122.7 (4ArC), 140.8 (2ArC), 142.1 (ArC), 149.4
(2ArC), 149.8 (4ArC), 152.4 (ArC), 164.9 (2C‚O), 165.1
(2C‚O); MS (m/z): (M+ 1) calculated 501.17; found
501.12; calculated for C25H23N7O5: C, 59.87; H, 4.62; N,
19.55; found C, 59.93; H, 4.67; N, 19.60.
2.5. Antimicrobial activity
The in vitro antibacterial activities were tested against
Gram-positive bacteria Bacillus subtilis and Gram-negativeantzsch 1,4-dihydropyridines.
82 K. Elumalai et al.bacteria Escherichia coli (E. coli) by a standard serial dilution
method using a stock solution of 100 lg/ml concentra-
tions.30,31 The double strength nutrient broth was used as cul-
ture media and dimethyl sulphoxide (DMSO) was used as
solvent control. The stock solutions of the test compounds
were serially diluted in test tubes containing 1 ml of sterile
medium to get different concentrations and then inoculated
with 100 lL of suspension of respective microorganisms in
sterile saline. Norfloxacin was used as standard drug. The
inoculated test tubes were incubated at 37 ± 1 C for 24 h.
2.6. In vitro cytotoxicity
Short-term in vitro cytotoxicity assay was performed using
Vero cells (African Monkey kidney cells), according to the
standard procedure. Sulforhodamine B (SRB) is a bright-
pink amino xanthene dye with two sulfonic groups.5 Under
mild acidic conditions, SRB binds to protein basic amino acid
residues in trichloroacetic acid fixed cells to provide a sensitive
index of cellular protein content that is linear over a cell den-
sity range of at least two orders of magnitude. After incuba-
tion, the solutions in the wells were flicked off and 100 ll of
different concentrations (2–500 lg) of compounds were added
to the cells and incubated at 37 C for 3 days in 5% CO2 atmo-
sphere. The microscopic examinations were performed and
observations were recorded every 24 h. After, 72 h, 50% tri-
chloroacetic acid (25 ll) was added to each well and the plates
were incubated for 1 h at 4 C. The supernatant was then
removed, and the cells were washed with water, air-dried,
and stained, each well with SRB for 30 min. The unbound
dye was removed by washing with 1% acetic acid and the
plates were air dried. Tris base (10 mM, 100 ll) was added to
wells to solubilize the dye. The plates were vigorously shaken
for 5 min, and the absorbance was measured using a Microtiter
plate reader at 540 nm. The mean absorbance of triplicate was
recorded. Mean observance taken from cells grown in the
absence of the test compound was taken as 100% cell survival
(control). The percentage growth inhibition was calculated
using the following formula:
Growth inhibition % ¼ 100 sample absorbance=control absorbance½ 
 1000 
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Figure 3 In vitro antimicrobial activity of compounds (4a–m)
and Norfloxacin (std).3. Result and discussion
A series of 13 novel isoniazid cyclocondensed 1,4-pyridines of
biological interest were synthesized and evaluated for antimi-
crobial activity and in vitro cytotoxicity, all the compounds
were characterized by IR, 1H NMR, 13C NMR, MS and ele-
mental analysis of their structures.
3.1. Chemistry
Synthesis of 1,4-pyridines by adopting the Hantzsch synthetic
protocol involving one-pot multicomponent reaction was per-
formed by following the steps as outlined in Fig. 1. In the first
step, ethyl acetoacetate 2 and isoniazid 1 and a catalytic
amount of potassium tert-butoxide8 was taken into a 250 ml
RB flask and dissolved in 15 ml of ethanol (95%) reacted
under neat conditions resulting in the formation of
N-(3-oxobutanoyl) isonicotinohydrazide 3 with the yield of71 percent. The N-(3-oxobutanoyl) isonicotinohydrazide 3
was further taken for the Hantzsch condensation reaction by
reacting it with appropriate aldehyde, a catalytic amount of
barium nitrate and 3 ml of 25–30% aqueous ammonia solu-
tion5 in the presence of 15 ml of ethanol.
The first step in the mechanism of the Hantzsch reaction is
the condensation of the b-ketoester with the aldehyde, it
produces Intermediate I, this reaction proceeding through
Knoevenagel condensation. In the second step b-ketoester
reacts with ammonia, it produces enamine Intermediate II.4
The further condensation between these two intermediates
gives the 1,4-dihydropyridine derivative (Fig. 2). The reaction
times were found to be 11–18 h. The IR spectra of compounds
4a–m are showing strong absorption bands for the amine
group (3286–3318 cm1), amide group (1664–1673 cm1), ali-
phatic CAH stretches (2922–3010 cm1), aromatic CAH
stretching (3081–3184 cm1), aromatic C‚C stretching
(1453–1487 cm1) and CAN (1328–1384 cm1). The 1H
NMR spectrum of compounds 4a–m is showing a two methyl
group proton singlet at 1.72–1.78 ppm, pyridine-CH-R proton
singlet at 4.44–4.58 ppm, pyridine-NH-proton singlet at 6.16–
6.24 ppm, aromatic proton multiplet at 5.86–9.15 ppm and
amide (NH) proton singlet at 8.04–8.34 ppm. The 13C NMR
spectra, mass spectra and elemental analysis results were
within ±0.6% of the theoretical values. Totally, thirteen com-
pounds 4a–m, various substituted 1,4-dihydropyridines, were
synthesized with the yield ranging from 56% to 81%. These
conditions enable this method to be applicable for the
synthesis of 1,4-dihydropyridines based heterocyclic com-
pounds. The present protocol best describes the synthesis of
1,4-dihydropyridines. All the reported 1,4-dihydropyridine
compounds were found to be novel and not reported
elsewhere.
3.2. Antimicrobial activity
The synthesized compounds were subjected to in vitro antimi-
crobial activity against Gram-positive bacteria B. subtilis,
Gram-negative bacteria E. coli. The motive is to check the
antimicrobial activity of the synthesized compounds. The
activity is expressed as minimum inhibitory concentration
(MIC), the lowest concentration of compound that completely
inhibited the growth on the culture.8 The antimicrobial activity
Table 1 Synthesized 1,4-dihydropyridines: in vitro antimicrobial activity and cytotoxicity.
N
H
R
N
H
O
H
N
O
N
N
H
O
H
N
O
N
General Structure of 1,4-dihydropyridines 
S. no. Compound R B. subtilis
MIC (lM)
E. coli
MIC (lM)
CTC50 (lM) on Vero Cells
1 4a 40.1 41.3 138
2 4b 36.1 37.3 110
3 4c
NO2
22.6 23.8 90
4 4d
Cl
20.4 21.6 69
5 4e
O2N
17.1 18.2 53
6 4f
Cl
15.7 16.6 46
7 4g
F
14.8 15.7 39
8 4h Cl 12.3 12.9 33
9 4i F 11.5 12.2 27
10 4j
N
36.7 38.2 90
11 4 k
N
31.5 32.8 74
12 4l N 29.2 31.1 68
13 4m
O
41.4 43.9 83
14 Norfloxacin Standard 11.8 12.5 –
15 Tamoxifen Standard – – 32
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The data listed in (Fig. 3 and Table 1) clearly showed that most
of the designed compounds exhibited good to moderate, orhigh antimicrobial activities toward the Gram-positive
B. subtilis and Gram-negative E. coli. All the 1,
4-dihydropyridines were potent antimicrobial agents, with an
Figure 5 Molecular structure of compound 4i.
Figure 6 3D-structure of compound 4i.
84 K. Elumalai et al.MIC value ranging from micro molar to submicromolar. Espe-
cially, compound 4i showed the best antimicrobial activity of
all the 1,4-dihydropyridine derivatives, with an MIC value of
11.5 lM and 12.2 lM.
3.3. In vitro cytotoxicity
The synthesized compounds were subjected to in vitro cytotox-
icity assay against Vero cells. The assay was performed by the
Sulforhodamine B (SRB) method. The in vitro cytotoxicity by
the SRB method was measured in lM. The motive for us to
check the cytotoxicity of the synthesized compounds was,
some reports that have claimed significant cytotoxicity for
some of the 1,4-dihydropyridines.5 The 1,4-dihydropyridines
act primarily by impairing cell reproductive integrity. Thus,
affected cells may remain alive and may continue to perform
many of their functions but are unable to reproduce success-
fully.15 The synthesis of DNA, RNA and other cell con-
stituents may continue at normal rates. However, the cell
either fails to divide, forming a giant cell, commences a divi-
sion that cannot be completed, or divides unsuccessfully,
resulting in chromosomes being unequally shared between
the daughter cells or being damaged in some way; these chro-
mosomal lesions may eventually cause cell death.16 The results
of the in vitro cytotoxicity study indicate that the compounds
4e, 4f, 4g, 4h and 4i enhance the cytotoxicity against Vero cells.
Compound 4i happens to be the most potent compound
among all the 1,4-dihydropyridines studied here by enhancing
the cytotoxicity with a CTC50 value of 27 lM. The rest of the
compounds exhibit weak to moderate cytotoxicity (Fig. 4 and
Table 1).
3.4. Structural activity relationship
Analyzing the biological activities of the synthesized com-
pounds, the following structure activity relationships (SAR)
were obtained. The third and fifth positions of 1,4-
dihydropyridines containing the isoniazid moiety seem to be
the hydrophobic trunk, which in turn is connected to the
1,4-dihydropyridines along with the amide bond, also seems
to be important structural components of the compounds
4a–m to exhibit significant antimicrobial activity and cytotox-
icity. This indicates the necessity of amide groups nearer to the0 
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Figure 4 In vitro cytotoxicity of compounds (4a–m) and
Tamoxifen (std).1,4-dihydropyridine head. The isonicotinoyl hydrazone ring
system is found to be the pharmacophore structural part as all-
most all compounds possessed this substructure. The differ-
ence in bioactivity of 1,4-dihydropyridines could be related
to the substituent’s at the fourth position of aryl ring.6
Compounds 4a–i contain a strong electron withdrawing group
substituted phenyl ring at the fourth position of
1,4-dihydropyridines for potent activity, because it decreases
the electron density in the ring, due to the inductive effect
(Figs. 5 and 6). The fluoride and chloride substitution at fourth
phenyl ring showed potent action because of strong electron
withdrawing nature.8,11 The substitution of the fluro and the
chloro group at the 3rd position of the phenyl ring showed
potent action when compared with the nitro group
substituted phenyl ring. The aryl substituent at the fourth posi-
tion of 1,4-hydropyridines order of potency has been found to
be 4-fluoro > 4-chloro > 3-fluoro > 4-pyridyl > 3-chloro >
3-nitro > 2-chloro > 2-nitro > H. Heteroaryl substituted
compounds at the fourth position showed moderate antimicro-
bial activity and cytototoxicity.14 The decreasing ring size from
the six membered ring to the five member furan (4 m) is found
to reduce the activity. Among the compounds reported herein,
compound 4i showed potent antimicrobial activity and cyto-
toxicity because the fluoride substituted aromatic ring present
at the fourth position of 1,4-dihydropyridines enhances the
compounds (Figs. 5, 6 and Table 1).
Synthesis,characterization, cytotoxicity of novel isoniazid condensed 1,4-dihydropyridines 854. Conclusion
A series of novel 1,4-dihydropyridines of biological interest
were synthesized and analyzed for their structures. The
libraries of compounds were prepared by using barium nitrate
as an efficient catalyst. The importance of substitutions at the
fourth positions of 1,4-dihydropyridines was studied toward
the antimicrobial activity and cytotoxicity. The antimicrobial
activity and cytotoxicity data revealed that the all synthesized
compounds proved to be active against Gram-positive bacteria
B. subtilis, Gram-negative bacteria E. coli and Vero cells.
Almost all of the titled compounds exhibited weak, moderate,
or high antimicrobial activity and cytotoxicity. Compound 4i
is arguably the most potent when compared with Norfloxacin
and Tamoxifen and our present study makes it an interesting
compound when compared to the current therapeutic agents
and is considered as the candidate to investigate further for
the same.Conflict of interest
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